Immunotherapy in Melanoma | Specialty

The OncLive Immunotherapy in Melanoma condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in melanoma and other skin cancers. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.

Guiding Treatment Decisions in Newly Diagnosed Metastatic Melanoma

January 16th 2020

Anna C. Pavlick, DO, discusses key trials that have shed light on how to best treat patients with newly diagnosed, metastatic melanoma.

Biomarker Hunt Finds Potential With ctDNA in Melanoma

January 16th 2020

David Polsky, MD, PhD, discusses the development and clinical utility of biomarkers in melanoma.

Adjuvant Therapy Transforms Treatment in Advanced Melanoma

January 16th 2020

Jeffrey S. Weber, MD, PhD, discusses the activity of targeted therapy in metastatic melanoma, its adoption into the adjuvant setting, and the optimal use of immunotherapy in the space.

SITC Poised to Expand Toolkit of Immunotherapy Guidelines

January 11th 2020

The Society for Immunotherapy of Cancer is developing a growing menu of guidelines with treatment algorithms for specific cancer types to help practicing oncologists navigate the appropriate use of this emerging modality.

Dr. Sznol on Immune-Related Toxicities in Melanoma

January 11th 2020

Mario Sznol, MD, discusses the adverse events that can occur from nivolumab in combination with ipilimumab for patients with melanoma.

Dr. Luke on Current and Emerging Treatment Approaches in Metastatic Melanoma

January 7th 2020

Jason J. Luke, MD, FACP, discusses current and emerging treatment paradigms in metastatic melanoma.

Dr. Sznol on Managing Patients Beyond Initial Treatment in Melanoma

January 3rd 2020

Mario Sznol, MD, discusses the management of patients with melanoma who progress on immune checkpoint inhibitors.

Dr. McQuade on Age as a Predictor of Response to Neoadjuvant Immunotherapy in Melanoma

December 14th 2019

Jennifer McQuade, MD, MS, MA, LAc, discusses how age may serve as a predictor of response to neoadjuvant immunotherapy for patients with melanoma.

Atezolizumab Plus Cobimetinib/Vemurafenib Meets PFS Endpoint in Frontline BRAF V600+ Advanced Melanoma

December 13th 2019

The triplet regimen of atezolizumab, cobimetinib, and vemurafenib was found to improve progression-free survival compared with cobimetinib/vemurafenib plus placebo in patients with previously untreated BRAF V600 mutation–positive advanced melanoma.

Dr. Marron on Shortening Treatment Duration of Immunotherapy in Melanoma

December 12th 2019

Thomas Marron, MD, PhD, discusses the potential benefit of shortening the length of immunotherapy treatment in melanoma.

The New Horizon in Melanoma

December 11th 2019

Jeffrey S. Weber, MD, PhD, looks to earlier use of immunotherapy and novel combinations in melanoma.

Dr. Daud on Dabrafenib/Trametinib Vs Immunotherapy in Melanoma

December 5th 2019

Adil Daud, MD, discusses the combination of dabrafenib and trametinib versus immunotherapy in patients with BRAF V600-mutant metastatic melanoma.

Spartalizumab Plus Dabrafenib/Trametinib Impresses in BRAF+ Melanoma With Poor Prognosis

November 27th 2019

A triplet combining the PD-1 inhibitor spartalizumab with dabrafenib and trametinib led to a 12-month overall survival rate of 86.1% for patients with previously untreated advanced BRAF V600–mutant melanoma.

Expert Weighs in on Targeted and Immunotherapy Combinations in Melanoma

November 26th 2019

Ryan J. Sullivan, MD, discusses the rationale for BRAF/MEK combinations and immunotherapeutic combinations in melanoma and ongoing research examining triplet regimens.

Expert Highlights Potential Markers of Nivolumab/Ipilimumab Response in Melanoma

November 26th 2019

Georgina V. Long, BSc, PhD, MBBS, FRACP, discusses the findings from a subgroup analyses of the CheckMate-067 trial.

Cobimetinib/Vemurafenib OS Benefit Sustained at 5 Years in BRAF+ Melanoma

November 25th 2019

The combination of cobimetinib (Cotellic) and vemurafenib (Zelboraf) maintained an advantage for overall survival and objective response rate in patients with BRAF-positive melanoma versus vemurafenib alone.

CR With Dabrafenib/Trametinib Linked to Long-Term Survival in BRAF+ Melanoma

November 24th 2019

Patients with unresectable or metastatic BRAF V600-mutant melanoma who achieve a complete response to dabrafenib (Tafinlar) plus trametinib (Mekinist) are more likely to have improved survival outcomes at 5 years.

Dr. Glitza on Intrathecal Nivolumab Approaches in Leptomeningeal Disease

November 24th 2019

Isabella C. Glitza, MD, discusses a single-center phase I/Ib trial of concurrent intravenous and intrathecal nivolumab for patients with metastatic melanoma and leptomeningeal disease.

Dr. McArthur Discusses Subpopulation Data from coBRIM Trial in Advanced Melanoma

November 23rd 2019

Grant McArthur, PhD, discusses significant results from the final analysis of the coBRIM trial, which evaluated the 5-year survival data of cobimetinib plus vemurafenib in patients with BRAF V600-mutated advanced melanoma.

Neoadjuvant T-VEC May Improve Survival in Advanced Melanoma

November 23rd 2019

Talimogene laherparepvec (T-VEC; Imlygic) prior to surgery was associated with improved recurrence-free survival and overall survival compared with surgery alone in patients with resectable advanced melanoma.